ClinicalTrials.gg
RecruitingNCT07447284ISAACUpdated Aug 27, 2026

The Improving Sleep in African American Couples Study (ISAAC)

An interventional study of CPAP Training and Education and Virtual Disease Support Group Sessions in Obstructive Sleep Apnea (OSA), sponsored by MetroHealth Medical Center. Recruiting at 2 sites in United States. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by MetroHealth Medical Center · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Study summary

The goal of this randomized study is to compare a combined behavioral intervention (remote tele-monitoring and feedback, virtual cognitive behavioral couple therapy, and couple-oriented peer support) on continuous positive airway pressure (CPAP) adherence, quality of sleep, functional status, and quality of life among patients with obstructive sleep apnea (OSA) and their bed partners.

Read the detailed description

This is a multiple site randomized controlled trial of 220 African American patients diagnosed with moderate to severe OSA and their bed partners. Half of the patients will receive optimal usual care, consisting of sleep therapist-initiated CPAP education and training. Patients will follow up with their sleep providers per usual. The remaining patients and their bed partners will receive a couple-oriented intervention consisting of optimal usual care. Couples will participate in couple-oriented support groups led by an African American patient with long standing OSA treated with CPAP and their partner. Patients and partners will receive tailored text messages encouraging adherence. In addition, couples will receive cognitive behavioral couple therapy sessions with a health psychologist trained in behavioral sleep medicine.

02

Conditions studied

  • Obstructive Sleep Apnea (OSA)

Keywords

  • Sleep Apnea Syndromes/Therapy
  • Continuous Positive Airway Pressure
  • Couples Therapy
03

In context

Sleep Apnea, Obstructive

2,240 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

This study's planned enrollment of 440 is above the median of 52 across 1,472 interventional studies indexed under Sleep Apnea, Obstructive.

Browse Sleep Apnea, Obstructive studies →

Lead sponsor

MetroHealth Medical Center is the lead sponsor of 104 studies on the registry; 20 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 7 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria - Patient:

  • Moderate or severe OSA (Apnea hypopnea index ≥ 15 events/hour)
  • Age ≥ 30 years
  • Bed partner for ≥ last 6 months who is willing to participate
  • English proficient

Inclusion Criteria - Bed Partner

  • Bed partner for ≥ 6 months and willing to participate
  • English proficient

Exclusion Criteria - Patient:

  • Terminal illness
  • Neurocognitive disorder that prevents
  • Unstable housing
  • Need for other forms of positive airway pressure (BPAP or VPAP)
  • Pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
440 participants (estimated)

Study arms

  • Placebo comparator
    Usual Care

    Patients will receive optimal standard of care in the management of OSA and will continue to meet with their health care providers per usual.

    Behavioral: CPAP Training and Education · Behavioral: Virtual Disease Support Group Sessions

  • Active comparator
    Couple-oriented Intervention Arm

    Patients will participate in usual care by their sleep providers. Patients and their bed partners will receive the following 1. CPAP instruction from sleep technologist 2. 3 virtual group sessions with an African American patient who regularly uses CPAP and their bed partner 3. Regular review of CPAP adherence with feedback to patient and bed partner when CPAP adherence changes 5\. 5 cognitive behavioral couple therapy sessions

    Behavioral: Couple CPAP Training and Education · Behavioral: Couples Virtual OSA Support Group Sessions · Behavioral: CPAP Tele-monitoring and Feedback · Behavioral: Couples' Cognitive Behavioral Therapy

Interventions

  • BehavioralCPAP Training and Education

    Sleep technologists will meet with patients to train them on CPAP use, upkeep, and troubleshooting.

  • BehavioralVirtual Disease Support Group Sessions

    Patients will attend 3 virtual webinars on prevention and management of diseases affecting the Black community including hypertension, obesity, cardiovascular disease, and cancer led by African American providers.

  • BehavioralCouple CPAP Training and Education

    Sleep technologists will meet with patients and their bed partners to train them on CPAP use, upkeep, and troubleshooting.

  • BehavioralCouples Virtual OSA Support Group Sessions

    Patient and their bed partner will participate in 3 virtual group sessions moderated by an African American patient with longstanding OSA who regularly uses CPAP and their bed partner.

  • BehavioralCPAP Tele-monitoring and Feedback

    Patients' CPAP adherence will be regularly monitored and automated feedback provided to patient and bed partner when there is change in CPAP use.

  • BehavioralCouples' Cognitive Behavioral Therapy

    Five cognitive behavioral couple therapy sessions will be provided to patients and their bed partners.

06

What researchers measure

Primary outcomes

  1. Mean Nightly CPAP Use at 1 Year

    Mean CPAP use at year will be the total hours of CPAP use divided by the number of days observed for the patient over the course of a year.

    Time frame: From enrollment until 1 year.

Secondary outcomes

  1. Mean Nightly CPAP Use

    Mean CPAP use will be the total hours of CPAP use divided by the number of days observed for the patient over the course of the designated time interval.

    Time frame: From enrollment to 30 days, 90 days, and 6 months.

  2. Patient and Bed Partner Quality of Sleep

    Epworth Sleepiness Scale

    Time frame: From enrollment to 30 days, 90 days, 6 months, and 1 year.

  3. Patient and Bed Partner Quality of Sleep

    PROMIS Sleep Disturbance Index

    Time frame: From enrollment to 30 days, 90 days, 6 months, and 1 year.

  4. Patient and Bed Partner Quality of Sleep

    PROMIS Sleep-Related Impairment

    Time frame: From enrollment to 30 days, 90 days, 6 months, and 1 year.

  5. Patient and Bed Partner Quality of Sleep

    Functional Outcomes of Sleep short version

    Time frame: From enrollment to 30 days, 90 days, 6 months, and 1 year.

  6. Patient and Bed Partner Quality of Sleep

    Actigraphy Data

    Time frame: 6 months

  7. Patient-Reported Measure of OSA Treatment

    Patient-Reported Longitudinal Assessment Tool for OSA (PLATO-11)

    Time frame: From enrollment to 30 days, 90 days, 6 months, and 1 year

  8. Patient and Bed Partner Quality of Life

    General quality of life will be assessed using the SF-12

    Time frame: From enrollment to 30 days, 90 days, 6 months, and 1 year.

  9. Sleep Apnea Beliefs

    Sleep apnea knowledge will be assessed using the Apnea Beliefs Scale.

    Time frame: From enrollment to 30 days, 90 days, 6 months, and 1 year.

  10. Sleep Apnea Knowledge

    Sleep apnea knowledge will be assessed using the Apnea Knowledge Test.

    Time frame: From enrollment to 30 days, 90 days, 6 months, and 1 year.

  11. Self-efficacy to Use CPAP

    Self-efficacy to use CPAP will be assessed using the Self-Efficacy Measure in Sleep Apnea (SEMSA).

    Time frame: From enrollment to 30 days, 90 days, 6 months, and 1 year.

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study data will be de-identified according to HIPAA and the Common Rule. It will subsequently be available through NHLBI BioData Catalyst.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Data will be available from 1 to 4 years after the conclusion of the study.

Access criteria: Those with access to NHLBI BioData Catalyst will have access to study data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.

Of 508 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 24 months is below that.

Counting every sponsor, half of 623 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2026
First posted
Mar 3, 2026
StartActual
Jul 24, 2026
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2028
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07447284
Responsible party
Daryl Thornton, MD (Principal Investigator, MetroHealth Medical Center) — Principal investigator
First posted
Mar 3, 2026
Start date
Jul 24, 2026
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Aug 27, 2026

Study contacts

Marquisha Marbury
Contact
mmarbury@metrohealth.org
216-778-8484
John Thornton, MD, MPH
principal investigator · MetroHealth System, Ohio

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion